Microcap Ledger Gyre Therapeutics, Inc. $GYRE
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- San Diego, CA
- Fiscal year end
- December 31
- Shares outstanding
- 111,509,849 [10-Q 2026-08-07]
What the company doesAI summary of filing
Gyre Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule therapies for organ fibrosis and inflammatory diseases. The company operates through a subsidiary in China and U.S. operations in San Diego. It generates revenue from three approved products marketed in China: ETUARY® (pirfenidone) for pulmonary fibrosis, which generated $106.1 million in 2025 sales; Etorel® (nintedanib) for fibrotic lung disease, launched in June 2025 with $4.6 million in 2025 sales; and Contiva® (avatrombopag) for liver-disease-related blood disorders, launched in March 2025 with $5.5 million in 2025 sales. The company is advancing a pipeline of clinical and preclinical candidates, including Hydronidone for liver fibrosis in both China and the United States, F573 for acute liver failure, F230 for pulmonary hypertension, and F528 for chronic obstructive pulmonary disease, all in China. [10-K 2026-03-13]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $53.53M | −$32.80M | −$13.55M | $43.29M | [10-Q 2026-08-07] |
| FY ended Dec 2025 | $116.59M | $9.88M | $1.01M | $49.19M | [10-K 2026-03-13] |
| FY ended Dec 2024 | $105.76M | $17.90M | −$3.64M | $11.81M | [10-K 2026-03-13] |
- Quarterly cash burn
- −$6.77M
- Cash runway Estimate
- ~19.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 93,521,434 | [10-Q 2024-11-13] |
| 2025-03-07 | 93,612,442 | [10-K 2025-03-17] |
| 2025-05-01 | 93,757,602 | [10-Q 2025-05-09] |
| 2025-07-31 | 96,313,157 | [10-Q 2025-08-11] |
| 2025-10-31 | 96,333,157 | [10-Q 2025-11-07] |
| 2026-03-02 | 96,963,611 | [10-K 2026-03-13] |
| 2026-05-01 | 97,028,322 | [10-Q 2026-05-08] |
| 2026-08-01 | 111,509,849 | [10-Q 2026-08-07] |
- Shelf registration
- S-3 filed 2026-06-23; declared effective 2026-08-03 [S-3 2026-06-23]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-01 | 8-K | Regulation FD disclosure |
| 2026-08-26 | 8-K | Regulation FD disclosure |
| 2026-08-07 | 10-Q | Quarterly report |
| 2026-08-07 | 8-K | Results of operations |
| 2026-07-16 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-07-15 | 8-K | Results of operations |
| 2026-07-13 | S-3/A | Registration statement |
| 2026-06-23 | S-3 | Registration statement |
| 2026-06-16 | 8-K | Shareholder vote results |
| 2026-06-02 | 8-K | Regulation FD disclosure |
| 2026-05-14 | 8-K | Regulation FD disclosure |
| 2026-05-12 | 8-K | Regulation FD disclosure |
Alerts for $GYRE
Email me when Gyre Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.